Paragon RX Clinical

1. Regeneron Pharmaceuticals, Inc. $956,746 53 payments
2. Cue Health Inc. $102,400 1 payment
3. Takeda Pharmaceuticals U.S.A., Inc. $60,379 7 payments
4. Organon LLC $12,250 5 payments
5. Arena Pharmaceuticals, Inc. $7,485 9 payments

1. Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Nsaid Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $956,746 53 payments
2. Clinical study for Flu $102,400 1 payment
3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2B Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of A Peripherally Acting Dopamine Receptor D2/D3 Antagonist, Tak-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic Or Diabetic Gastroparesis $54,679 6 payments
4. Og-8175A-023 $12,250 5 payments
5. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis $7,485 9 payments
6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2B Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of A Peripherally Acting Dopamine Receptor D2/D3 Antagonist, Tak-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic Or Diabetic Gastroparesis $5,700 1 payment

1. Patient care $12,250 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.